Hypertension in older adults presents a clinical challenge that is qualitatively different from hypertension in younger patients. The dominant pattern is isolated systolic hypertension (ISH), driven by age-related arterial stiffness rather than the neurohormonal mechanisms that predominate in younger hypertensives.
The pharmacological treatment of hypertension in the elderly is strongly supported by clinical trial evidence showing substantial reductions in stroke, heart failure, and cardiovascular mortality, yet it requires careful individualization to avoid the adverse effects that disproportionately affect older patients: orthostatic hypotension, falls, acute kidney injury (AKI), electrolyte disturbances, and cognitive impairment. This module addresses the vascular biology of aging and ISH, the landmark trial evidence establishing treatment benefit in older adults including the very elderly, evidence-based blood pressure (BP) targets, preferred and avoided drug classes, and the clinical framework for individualizing therapy based on frailty and comorbidity.
The aging vasculature undergoes a series of structural and functional changes that collectively produce increased arterial stiffness.1,2 Elastin fibers in the aortic wall fragment with age and are replaced by stiffer collagen fibers, progressively reducing aortic compliance. Advanced glycation end products (AGEs) cross-link collagen molecules, further stiffening the arterial wall. In parallel, intimal thickening and endothelial dysfunction develop: reduced nitric oxide (NO) production from aging endothelium reduces vasodilatory capacity, while increased reactive oxygen species accelerate oxidative stress in the vessel wall. Medial calcification, which is distinct from intimal atherosclerotic calcification, adds an additional component of reduced compliance.
The hemodynamic consequence of reduced aortic compliance is widening of pulse pressure (PP = systolic blood pressure [SBP] − diastolic blood pressure [DBP]). Under normal conditions, the compliant aorta expands during systole to absorb part of the stroke volume (the Windkessel effect) and recoils during diastole to maintain diastolic pressure and coronary perfusion. In the stiff aging aorta, this buffering is lost: SBP rises markedly because the pressure wave is no longer damped, and DBP falls because elastic recoil is absent. The result is ISH, defined as SBP ≥140 mmHg with DBP <90 mmHg. Pulse pressure exceeding 60–70 mmHg in elderly patients predicts particularly high cardiovascular event rates.
Pulse wave velocity (PWV), the speed at which the arterial pressure wave travels through the aorta, is a direct measure of arterial stiffness. Normal young adults have PWV of approximately 5–7 m/s; elderly hypertensives may reach 10–15 m/s or higher, with higher PWV predicting cardiovascular events independently of peripheral BP. With increased PWV, the reflected pressure wave returns to the aorta during systole rather than during diastole, augmenting systolic pressure further. This wave augmentation is quantified as the augmentation index (AIx), which is elevated in elderly patients and is an independent marker of cardiovascular risk.
ISH is the dominant pattern of hypertension in patients over 60 years of age. Systolic BP is a more powerful predictor of cardiovascular risk than diastolic BP in patients over 50–55 years old. The therapeutic goal is to lower SBP while avoiding a disproportionate fall in DBP: reducing DBP below 65–70 mmHg in patients with established coronary artery disease (CAD) risks impairing coronary perfusion and represents the clinical basis of the J-curve phenomenon in this population.
The Systolic Hypertension in the Elderly Program (SHEP, 1991) enrolled 4,736 patients aged ≥60 years with ISH (SBP 160–219 mmHg; DBP <90 mmHg) and randomized them to chlorthalidone-based therapy versus placebo.3 Active treatment produced a 36% reduction in stroke, 32% reduction in major cardiovascular events, 54% reduction in left ventricular failure, and 27% reduction in coronary events. SHEP established for the first time that treating ISH in the elderly provides substantial cardiovascular protection, with chlorthalidone as the cornerstone agent confirming thiazide-like diuretics as first-line therapy in this population.
The Systolic Hypertension in Europe trial (Syst-Eur, 1997) enrolled 4,695 patients aged ≥60 years with ISH and randomized them to nitrendipine, a dihydropyridine (DHP) calcium channel blocker (CCB), versus placebo.4 Active treatment produced a 42% reduction in stroke, 31% reduction in all cardiovascular events, and 26% reduction in cardiac endpoints, establishing DHP CCBs as equally effective first-line agents for elderly ISH and complementing the SHEP diuretic evidence.
The Hypertension in the Very Elderly Trial (HYVET, 2008) enrolled 3,845 patients aged ≥80 years (mean age 83.6 years) with SBP ≥160 mmHg and randomized them to indapamide 1.5 mg sustained-release with or without perindopril 2–4 mg versus placebo.5 Active treatment produced a 30% reduction in stroke (primary endpoint; trend), a 21% reduction in all-cause mortality (p=0.02), a 64% reduction in heart failure, and a 23% reduction in cardiovascular death. A particularly important finding was that the active treatment group had fewer serious adverse events than placebo, demonstrating that antihypertensive treatment in the very elderly is safe and well-tolerated. HYVET established that treatment in patients ≥80 years reduces mortality, with indapamide combined with perindopril as the evidence-based regimen for this age group.
The SPRINT trial (2015) included an elderly subgroup of 2,636 patients aged ≥75 years randomized to an intensive SBP target (<120 mmHg by automated unattended measurement) versus a standard target (<140 mmHg).6,9 Intensive treatment reduced composite cardiovascular events by 34% and all-cause mortality by 33% in this age group. Rates of AKI, syncope, and electrolyte disturbances were higher with intensive treatment, but the benefit-risk ratio remained favorable for non-frail elderly patients. An important methodological note: SPRINT used automated unattended BP measurement, producing readings approximately 5–10 mmHg lower than standard office measurement; SPRINT's "120 mmHg" target corresponds to approximately 130 mmHg by standard clinical measurement. The ACCORD blood pressure trial found no significant reduction in the primary cardiovascular endpoint with intensive SBP control (<120 mmHg) in elderly diabetic patients, with a significant increase in adverse events, reinforcing that very low BP targets are not appropriate in all elderly populations.
The ACC/AHA 2017 guidelines recommend a target of <130/80 mmHg for community-dwelling ambulatory adults aged ≥65 years, with individualization based on comorbidities, life expectancy, and tolerability.1 The 2023 ESH guidelines take a more conservative position: for patients aged 65–79 years, the recommended SBP target is 130–139 mmHg; for patients aged ≥80 years, the initial target is SBP 140–149 mmHg, with lower targets (130–139 mmHg) pursued only if tolerated without adverse effects.2 NICE guidelines recommend offering treatment to adults aged ≥80 years with SBP consistently ≥150 mmHg, targeting SBP 150 mmHg or lower, with lower targets if tolerated and frailty allows.
The J-curve phenomenon, in which excessive lowering of BP (particularly DBP) is associated with worse outcomes, is most clinically relevant in elderly patients with established CAD. Coronary perfusion occurs predominantly during diastole and depends on adequate DBP. Reducing DBP below 65–70 mmHg in patients with significant coronary stenosis may reduce perfusion pressure distal to the stenosis. The J-curve is most pronounced in patients with wide pulse pressure (>70 mmHg), established CAD, or reduced left ventricular (LV) systolic function. Practical guidance: avoid reducing DBP below 65 mmHg in elderly patients and monitor closely for symptoms of hypoperfusion including angina, dizziness, and pre-syncope.
Frailty significantly modifies the risk-benefit calculation for intensive BP treatment.7 The Fried frailty phenotype (five criteria: unintentional weight loss, self-reported exhaustion, weak grip strength, slow walking speed, and low physical activity; frail if ≥3 criteria are present) and the Clinical Frailty Scale (CFS, 1–9 from very fit to terminally ill) are practical assessment tools. For fit elderly patients (CFS 1–3), evidence supports targeting <130 mmHg SBP. For pre-frail patients (CFS 4–5), standard targets (<140 mmHg SBP) with careful monitoring are appropriate. For frail patients (CFS 6–8), targets should be individualized with focus on quality of life and symptom burden; de-prescribing may be appropriate when multiple antihypertensives are producing adverse effects without demonstrable benefit. For very frail or end-of-life patients, withdrawal of antihypertensives should be actively considered when not tolerated.
Thiazide-like diuretics (chlorthalidone, indapamide) are among the most effective antihypertensives in elderly ISH, anchored by SHEP (chlorthalidone) and HYVET (indapamide) trial evidence.3,5 They are particularly effective in the low-renin, volume-dependent hypertension typical of elderly patients. Preferred dosing: chlorthalidone 12.5–25 mg or indapamide 1.25–2.5 mg once daily. Monitoring requirements include sodium (hyponatremia risk is higher in elderly women; start at the lowest dose with sodium recheck within 2–4 weeks), potassium, uric acid, glucose, and creatinine. Orthostatic BP should be checked in both sitting and standing positions at every visit in elderly patients on diuretics.
DHP CCBs (amlodipine, long-acting nifedipine) are highly effective for ISH through a renin-independent mechanism, validated by Syst-Eur trial evidence and particularly valuable in elderly low-renin hypertension.4 No dose adjustment is required in the elderly; there are no adverse renal or metabolic effects and no electrolyte disturbances. Peripheral edema, the most common adverse effect, is more pronounced in the elderly and can be managed by combining with a renin-angiotensin-aldosterone system (RAAS) inhibitor or reducing the dose. Amlodipine is preferred for its long half-life (35–50 hours), which provides smooth 24-hour BP control without significant reflex tachycardia and a pharmacokinetic buffer for occasional missed doses.
ACEi and ARBs are appropriate when compelling indications are present, including chronic kidney disease (CKD) with proteinuria, heart failure with reduced ejection fraction (HFrEF), post-myocardial infarction (MI), and diabetes with nephropathy. They are less effective as monotherapy in elderly ISH (low-renin states) unless combined with a diuretic or CCB. ARBs are preferred over ACEi in elderly patients in whom ACEi-related cough would be particularly problematic. HYVET added perindopril to indapamide for patients not at BP target, supporting ACEi as a useful second agent in the very elderly. Creatinine and potassium should be monitored carefully; the elderly kidney is more susceptible to functional AKI with RAAS inhibition.
Beta-blockers are not preferred as first-line therapy for uncomplicated ISH in the elderly: they are less effective for isolated systolic BP reduction and carry increased risk of fatigue, exercise intolerance, falls, depression, sexual dysfunction, and cold extremities. They should be used when compelling indications are present including HFrEF, post-MI, and atrial fibrillation (AF) rate control. When required, cardioselective agents (bisoprolol, nebivolol) are preferred; atenolol should be avoided due to renal accumulation in CKD and inferior outcomes demonstrated in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial.8
Alpha-1 blockers (doxazosin, terazosin) carry significant risk of orthostatic hypotension and first-dose syncope in the elderly, with attendant falls and hip fracture risk. The ALLHAT trial demonstrated increased heart failure with doxazosin as monotherapy.12 They have a useful niche in elderly men with concurrent benign prostatic hyperplasia (BPH) but should be used only as add-on therapy initiated at the lowest dose at bedtime, not as antihypertensive monotherapy. Centrally acting agents (clonidine, methyldopa) carry increased risk of sedation, cognitive impairment, depression, and falls in the elderly and should be used only as adjuncts when other options have failed. Short-acting DHP CCBs (immediate-release nifedipine) are contraindicated for hypertension management in the elderly; exaggerated reflex tachycardia and BP variability may be particularly harmful in elderly patients with CAD.
Multiple age-related physiological changes alter drug pharmacokinetics in elderly patients, requiring dosing adjustments and more careful monitoring.2 Glomerular filtration rate (GFR) declines approximately 1 mL/min/year after age 40; renally excreted drugs accumulate (atenolol, lisinopril, digoxin) and dose reduction is required. The CKD-EPI equation rather than serum creatinine alone should be used to estimate GFR accurately in the elderly, because reduced muscle mass means creatinine production is lower and serum creatinine alone overestimates GFR. Reduced hepatic blood flow and first-pass metabolism increase the bioavailability of hepatically metabolized agents including labetalol, metoprolol, propranolol, nifedipine, amlodipine, verapamil, and diltiazem.
Altered body composition in the elderly, specifically reduced lean body mass and increased fat mass, changes the volume of distribution of drugs. Lipophilic drugs (metoprolol, propranolol, lipophilic statins) have larger volumes of distribution and longer effective half-lives. Reduced plasma albumin, common in frail elderly patients, increases the free fraction of highly protein-bound drugs. The blood-brain barrier function is altered in aging; lipophilic drugs cross more readily, increasing central nervous system (CNS) sensitivity to sedating effects of clonidine, methyldopa, lipophilic beta-blockers, and benzodiazepines. Finally, the average elderly hypertensive patient takes 5–7 prescription medications in addition to antihypertensives; drug-drug interactions are a major source of adverse effects including additive hypotension, AKI, and hyperkalemia. Non-steroidal anti-inflammatory drugs (NSAIDs), often taken for musculoskeletal pain, antagonize both diuretics and RAAS inhibitors and must be specifically identified at every medication review.
Orthostatic hypotension (OH) is defined as a fall in SBP ≥20 mmHg or DBP ≥10 mmHg within 3 minutes of standing from a supine or seated position. Its prevalence is approximately 20% of elderly patients in community settings, rising above 50% in institutionalized elderly, and it is associated with approximately a 2-fold increased risk of falls, syncope, and cardiovascular events.11 All antihypertensives can worsen OH; alpha-1 blockers, loop diuretics, and CCBs are most problematic. BP should be checked in both sitting or supine and standing positions at every visit in elderly hypertensive patients. Management includes review and simplification of the antihypertensive regimen, optimization of dose timing (avoiding diuretics in the evening), ensuring adequate hydration, compression stockings, advice on slow positional changes, and avoidance of alcohol. Midodrine is reserved for refractory cases.
Hypertension itself is a major modifiable risk factor for dementia and cognitive decline; treating hypertension preserves cognitive function. Certain antihypertensive agents, however, have CNS effects in the elderly that require consideration. Lipophilic beta-blockers (metoprolol, propranolol) are associated with fatigue, sleep disturbance, depression, and mild cognitive effects at high doses. Centrally acting agents (clonidine, methyldopa) cause sedation, confusion, and falls and are generally avoided in the elderly. Excessive BP lowering (to below 110–120/60–70 mmHg) may paradoxically impair cerebral perfusion in patients with cerebral autoregulatory dysfunction, particularly those with small vessel disease or prior stroke. Cognitively neutral preferred agents include amlodipine, chlorthalidone, and ARBs.
In elderly patients, particularly those who are frail or have multiple comorbidities, a conservative initiation strategy is essential. Begin at half the standard starting dose when possible (chlorthalidone 6.25 mg, amlodipine 2.5 mg, perindopril 2 mg), titrate slowly every 4–6 weeks rather than every 2–4 weeks, and add second agents only after confirming tolerance and stability of the first. The complete medication list should be reviewed at every visit. In frail elderly patients experiencing falls, orthostatic hypotension, or declining quality of life attributable to antihypertensive therapy, withdrawal or dose reduction (de-prescribing) should be actively considered rather than reflexively avoided.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127–e248.
doi:10.1016/j.jacc.2017.11.006Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071.
doi:10.1097/HJH.0000000000003480SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension (SHEP). JAMA. 1991;265(24):3255–3264.
doi:10.1001/jama.1991.03460240051032Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension (Syst-Eur). Lancet. 1997;350(9080):757–764.
doi:10.1016/S0140-6736(97)05381-6Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older (HYVET). N Engl J Med. 2008;358(18):1887–1898.
doi:10.1056/NEJMoa0801369SPRINT Research Group; Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control (SPRINT). N Engl J Med. 2015;373(22):2103–2116.
doi:10.1056/NEJMoa1511939Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–M156.
doi:10.1093/gerona/56.3.M146Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE). Lancet. 2002;359(9311):995–1003.
doi:10.1016/S0140-6736(02)08089-3Williamson JD, Supiano MA, Applegate WB, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years (SPRINT elderly subgroup). JAMA. 2016;315(24):2673–2682.
doi:10.1001/jama.2016.7050Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003;21(12):2409–2417.
doi:10.1097/00004872-200312000-00030Gangavati A, Hajjar I, Quach L, et al. Hypertension, orthostatic hypotension, and the risk of falls in a community-dwelling elderly population. J Am Geriatr Soc. 2011;59(3):383–389.
doi:10.1111/j.1532-5415.2011.03317.xALLHAT Officers and Coordinators. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic (ALLHAT). JAMA. 2002;288(23):2981–2997.
doi:10.1001/jama.288.23.2981Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure (CAMELOT). JAMA. 2004;292(18):2217–2225.
doi:10.1001/jama.292.18.2217Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Am Coll Cardiol. 2011;57(20):2037–2114.
doi:10.1016/j.jacc.2011.01.008Tsujimoto T, Kajio H. Benefits of intensive blood pressure treatment in patients with type 2 diabetes mellitus receiving standard but not intensive glycemic control. Hypertension. 2018;72(2):323–330.
doi:10.1161/HYPERTENSIONAHA.118.11052